Magnasense logotype


Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website,, launched on 9 July 2024, with redirects from

AegirBio presentation and discussion session at ECTRIMS 2022

PRESSRELEASE       September 6, 2022 AegirBio AB is pleased to announce that its abstract entitled “Quantitation of bivalent and monovalent natalizumab: providing a tool to study effects of IgG4 arm exchange.” has been accepted for poster presentation at the upcoming ECTRIMS 2022 congress to be held in Amsterdam on the 26-28 of October 2022.

The ECTRIMS congress is the world’s largest gathering of neurologists and scientists focused on Multiple Sclerosis (MS). In addition to planned marketing outreach, including a booth in the exhibition hall, the company will be hosting a “Brain Exchange”. This open discussion session led by a panel of experts, including MS key opinion leader Dr John Foley, is tentatively titled “The case for therapeutic drug monitoring (TDM) of biologic therapies used in Multiple Sclerosis” and will explore personalized dosing in clinical practice.


All of these activities are designed to showcase AegirBio’s recently approved point of care TDM test for natalizumab (originally launched by Biogen under the brand name Tysabri®), one of the leading drugs used to treat MS. 


“It was at the 2019 ECTRIMS congress in Stockholm that our Chairman of the Board, Anders Ingvarsson, and I, then CEO of Abreos Biosciences, laid the foundations for what would become AegirBio. It is therefore exciting, 3 years later, to present our fully developed product to the MS community and to get first-hand feedback on its utility from future users” said Bradley Messmer, CEO of AegirBio. He added “Our approved product is the first of its kind and answers the current need for measurements of total natalizumab levels in treated patients. Our poster describes the next generation of the technology.”


The company’s poster presentation describes a novel use of our VeritopeTM platform to distinguish between the two forms of the drug molecule found in treated patients. This data may aid physicians in clinical decision making when using natalizumab in MS patients. A scientific manuscript on this topic has been accepted for peer reviewed publication in the journal “Therapeutic Drug Monitoring” and the technology is covered by a pending patent application.


More information about ECTRIMS 2022 can be found here:

About AegirBio

AegirBio is a Swedish diagnostics company that was founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results.

About Veritope

The Veritope Platform is a proprietary reagent platform based on peptide mimetopes that detect a given biologic drug by mimicking the natural ligand target, including cell membrane bound proteins. Veritopes specifically detect the target biologic or biosimilar drug in human samples such as serum, plasma, or saliva. This enables rapid analysis of drug levels in patients and may aid clinical decision making to optimize dosing, thereby reducing side effects and cost.

About multiple sclerosis

Multiple Sclerosis is a chronic autoimmune neurological disease characterized neurodegeneration. It affects over 2.5 million people worldwide (and over 700 000 in Europe alone) and represents a huge financial and emotional burden to patients and their families. The course of MS is highly varied among individuals, but in many patients is characterized by episodes of reversible neurological deficits followed by progressive neurological deterioration over time.

Related links: